A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE with D-tryptophan substitution at residue 6.
Broad spectrum antinematodal anthelmintic used also in veterinary medicine.
Pyrvinium compounds are antihelminthic agents, specifically pyrazinylquinolines, that have been used in the treatment of intestinal infections caused by certain parasitic worms, such as pinworms and hookworms, by inhibiting their microtubular function and causing severe vacuolation within the worm's tissues.
Chemical compounds causing LUTEOLYSIS or degeneration.
A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920)
Infection of humans or animals with hookworms of the genus ANCYLOSTOMA. Characteristics include anemia, dyspepsia, eosinophilia, and abdominal swelling.
A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND.
Infection of humans or animals with hookworms of the genus NECATOR. The resulting anemia from this condition is less severe than that from ANCYLOSTOMIASIS.
A genus of nematode intestinal parasites that consists of several species. A. duodenale is the common hookworm in humans. A. braziliense, A. ceylonicum, and A. caninum occur primarily in cats and dogs, but all have been known to occur in humans.
Infection of horses with parasitic nematodes of the superfamily STRONGYLOIDEA. Characteristics include the development of hemorrhagic nodules on the abdominal peritoneum.
Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
A common parasite of humans in the moist tropics and subtropics. These organisms attach to villi in the small intestine and suck blood causing diarrhea, anorexia, and anemia.
Acetylated sulfone that is slowly metabolized to give long-term, low blood levels of DAPSONE. It has antimicrobial and antimalarial action, but is mainly used as a depot leprostatic agent.
A genus of nematode worms comprising the whipworms.
Infections with true tapeworms of the helminth subclass CESTODA.
Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.
Agents destructive to parasitic worms. They are used therapeutically in the treatment of HELMINTHIASIS in man and animal.
Hormones produced by the GONADS, including both steroid and peptide hormones. The major steroid hormones include ESTRADIOL and PROGESTERONE from the OVARY, and TESTOSTERONE from the TESTIS. The major peptide hormones include ACTIVINS and INHIBINS.
Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Follicle-stimulating hormone stimulates GAMETOGENESIS and the supporting cells such as the ovarian GRANULOSA CELLS, the testicular SERTOLI CELLS, and LEYDIG CELLS. FSH consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity.
A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
Receptors with a 6-kDa protein on the surfaces of cells that secrete LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE, usually in the adenohypophysis. LUTEINIZING HORMONE-RELEASING HORMONE binds to these receptors, is endocytosed with the receptor and, in the cell, triggers the release of LUTEINIZING HORMONE or FOLLICLE STIMULATING HORMONE by the cell. These receptors are also found in rat gonads. INHIBINS prevent the binding of GnRH to its receptors.
Techniques for the artifical induction of ovulation, the rupture of the follicle and release of the ovum.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A major gonadotropin secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). Luteinizing hormone regulates steroid production by the interstitial cells of the TESTIS and the OVARY. The preovulatory LUTEINIZING HORMONE surge in females induces OVULATION, and subsequent LUTEINIZATION of the follicle. LUTEINIZING HORMONE consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is common in the three pituitary glycoprotein hormones (TSH, LH and FSH), but the beta subunit is unique and confers its biological specificity.
Tests that demonstrate the relative effectiveness of chemotherapeutic agents against specific parasites.
A complication of OVULATION INDUCTION in infertility treatment. It is graded by the severity of symptoms which include OVARY enlargement, multiple OVARIAN FOLLICLES; OVARIAN CYSTS; ASCITES; and generalized EDEMA. The full-blown syndrome may lead to RENAL FAILURE, respiratory distress, and even DEATH. Increased capillary permeability is caused by the vasoactive substances, such as VASCULAR ENDOTHELIAL GROWTH FACTORS, secreted by the overly-stimulated OVARIES.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.
Substances that are destructive to protozoans.
Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy.
The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.
A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM.
An assisted fertilization technique consisting of the microinjection of a single viable sperm into an extracted ovum. It is used principally to overcome low sperm count, low sperm motility, inability of sperm to penetrate the egg, or other conditions related to male infertility (INFERTILITY, MALE).
The transfer of mammalian embryos from an in vivo or in vitro environment to a suitable host to improve pregnancy or gestational outcome in human or animal. In human fertility treatment programs, preimplantation embryos ranging from the 4-cell stage to the blastocyst stage are transferred to the uterine cavity between 3-5 days after FERTILIZATION IN VITRO.
The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
An assisted reproductive technique that includes the direct handling and manipulation of oocytes and sperm to achieve fertilization in vitro.

Uterine peristalsis during the follicular phase of the menstrual cycle: effects of oestrogen, antioestrogen and oxytocin. (1/197)

Uterine peristalsis, directing sustained and rapid sperm transport from the external cervical os or the cervical crypts to the isthmic part of the tube ipsilateral to the dominant follicle, changes in direction and frequency during the menstrual cycle, with lowest activity during menstruation and highest activity at mid cycle. It was therefore suggested that uterine peristalsis is under the control of the dominant follicle with the additional involvement of oxytocin. To test this hypothesis, vaginal sonography of uterine peristalsis was performed in the early, mid and late proliferative phases, respectively, of cycles of women treated with oestradiol valerate and with human menopausal gonadotrophin following pituitary downregulation, with clomiphene citrate and with intravenous oxytocin, respectively. Administration of oestradiol valerate resulted in oestradiol serum concentrations comparable with the normal cycle with a simulation of the normal frequency of peristaltic contractions. Elevated oestradiol concentrations and bolus injections of oxytocin resulted in a significant increase in the frequency of peristaltic contractions in the early and mid follicular phases, respectively. Chlomiphene tended, though insignificantly so, to suppress the frequency of peristaltic waves in the presence of elevated oestradiol concentrations. In the late follicular phase of the cycle extremely elevated oestradiol concentrations as well as the injection of oxytocin resulted only in an insignificant further increase of peristaltic frequency. In the normal cycles, as well as during extremely elevated oestradiol concentrations and following oxytocin administration, the peristaltic contractions were always confined to the subendometrial layer of the muscular wall. The results and the review of literature indicate that uterine peristalsis during the follicular phase of the menstrual cycle is controlled by oestradiol released from the dominant follicle with the probable involvement of oxytocin, which is presumably stimulated together with its receptor within the endometrial-subendometrial unit and therefore acting in an autocrine/paracrine fashion. Since unphysiological stimulation with oestradiol and oxytocin did not significantly increase the frequency of uterine peristalsis in the late follicular phase of the cycle it is assumed that normal preovulatory frequency of uterine peristalsis is at a level which cannot be significantly surpassed due to phenomena of refractoriness of the system.  (+info)

Paracrine changes in the peritoneal environment of women with endometriosis. (2/197)

During the past decade, macrophage-derived substances such as prostanoids, cytokines, growth factors and angiogenic factors have been detected in the peritoneal fluid of women with endometriosis. In particular, growth-promoting and angiogenic factors are considered to be substantially involved in the pathogenesis of endometriosis. In this study, vascular endothelial growth factor (VEGF), transforming growth factor beta (TGF-beta) and intercellular adhesion molecule 1 (ICAM-1), substances recently detected in the peritoneal fluid of women with endometriosis, were assessed with regard to their concentrations in different stages of endometriosis and changes of the peritoneal paracrine activity after medical treatment with a gonadotrophin releasing hormone agonist (GnRHa). Peritoneal fluid was obtained from patients with endometriosis during laparoscopy before and after a 4-month treatment with a GnRHa. VEGF, TGF-beta and ICAM-1 could be detected in all women presenting with various stages of active endometriosis. After GnRHa therapy, all patients showed significant decreases in mean concentrations of VEGF (194+/-77 pg/ml), TGF-beta (902+/-273 pg/ml) and ICAM-1 (157+/-52 ng/ml). Patients with stage III and IV endometriosis (according to the rAFS score) had much higher concentrations of VEGF and TGF-beta before treatment compared with those patients with mild endometriosis (rAFS stages I and II). The most striking decrease in concentration was for TGF-beta, from 902 pg/ml before to 273 pg/ml after therapy. These results indicate an important role for paracrine activity in the establishment and maintenance of endometriosis. Indeed, treatment with a GnRHa may reduce paracrine activity in the peritoneal cavity via hypo-oestrogenism and provide proof of successful therapy.  (+info)

Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. (3/197)

Endometrial hyperplasia is thought to be caused by the prolonged, unopposed oestrogenic stimulation of the endometrium. The regression of hyperplastic back to normal endometrium is the main purpose of any conservative treatment in order to prevent development of adenocarcinoma. The aim of this study was to evaluate the regression of hyperplastic to normal endometrium in patients with various forms of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue (GnRHa) triptorelin for 6 months. Fifty-six patients with endometrial hyperplasia were enrolled in this trial; 39 patients (group I) presented simple hyperplasia, 14 (group II) complex hyperplasia and three (group III) atypical complex hyperplasia. All patients were treated with triptorelin for 6 months. Bleeding control during treatment was excellent. A post-treatment curettage for estimation of endometrial histology was performed on 54 out of 56 patients 100.1 +/- 44.7 days after the last triptorelin dose, following the restoration of pituitary function. Regression of hyperplastic to normal endometrium was observed in 32 (86.5%) out of 37 patients in group I and in 12 (85.7%) out of 14 in group II. Persistence of simple hyperplasia was found in five (14.5%) out of 37 patients in group I. Persistence of complex hyperplasia was found in 1 (7.1%) out of 14 patients and progression to atypical complex hyperplasia in another one (7.1%) woman in group II. In some of these cases, the presence of risk factors such as obesity, diabetes mellitus and ovulatory disturbances may contribute to the disease persistence despite therapy. On the other hand, in group III, none of the three patients had normal post-treatment endometrial histology. It seems, therefore, that in cases of endometrial hyperplasia without atypia, the administration of the GnRHa triptorelin is associated with high regression rates to normal endometrium. Conversely, the presence of atypia seems to be a poor prognostic factor. Treatment tolerance and bleeding control during therapy is excellent.  (+info)

Treatment of uterine fibroid with triptorelin before hysterectomy. (4/197)

OBJECTIVE: To study the effects of pretreatment with triptorelin on uterine fibroid before abdominal hysterectomy. METHODS: Fifteen premenopausal Chinese women with symptomatic uterine fibroids requiring hysterectomy were recruited in the study. All patients received monthly intramuscular injections of 3.75 mg triptorelin for three months prior to abdominal hysterectomy. RESULTS: There was significant reduction in the serum levels of oestradiol (68.6%), progesterone (95.6%) and luteinizing hormone (73.9%) and in uterine (45.0%) and fibroid (68.0%) volumes. The serum level of follicle-stimulating hormone and haemoglobin concentration were not significantly different. CONCLUSIONS: Shrinkage of uterine fibroids can be achieved in women who are rendered hypoestrogenic with monthly injections of triptorelin for three months. This treatment modality may be of value prior to hysterectomy or myomectomy especially when the fibroid is large.  (+info)

Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. (5/197)

OBJECTIVE: Serum leptin concentration shows a sexual dimorphism that is not accounted for by gender differences in adiposity. A strong inverse association exists between serum leptin and testosterone concentrations in men, pointing to a likely influence of gonadal sex steroids on serum leptin concentration. The aim of this study was to investigate whether manipulation of sex steroid hormones in men would alter serum leptin concentration independently of changes in fat mass. DESIGN AND METHODS: The effects of sex steroid suppression on serum leptin concentration were investigated in nine healthy men in whom testosterone had been reversibly suppressed for 5 weeks after treatment with intramuscular triptorelin. The effects of sex steroid supplementation were investigated in nine male bodybuilders who self-administered anabolic--androgenic steroids (AAS) for a mean period of 6.5 weeks. A control group received no hormonal treatment. RESULTS: Testosterone concentration was significantly reduced by triptorelin administration (7.32+/- 1.92ng/ml at baseline compared with 1.15+/-0.57ng/ml at 5 weeks, P=0.002). High-dose AAS use was confirmed by urine analysis. Body fat percentage was unaffected by the AAS or triptorelin intervention (P>0.19). Leptin concentration was significantly reduced after one cycle of AAS use (2.40+/-0. 98ng/ml off cycle compared with 1.63+/-0.37ng/ml on cycle, P=0.012), and was significantly increased by triptorelin administration (2. 96+/-1.50ng/ml at baseline compared with 6.63+/-4.67ng/ml at five weeks, P=0.004). No significant change occurred in the control group. CONCLUSION: Androgenic sex hormone supplementation decreases serum leptin concentration, whereas suppression increases serum leptin concentration, independently of changes in body fat mass in healthy men. The sexual dimorphism evident in serum leptin concentration is likely to be due to a suppressive effect of testosterone on serum leptin concentration in males.  (+info)

Premenstrual attacks of acute intermittent porphyria: hormonal and metabolic aspects - a case report. (6/197)

We report the case of a 38-year-old woman with acute intermittent porphyria (AIP). Following the observation of an acute AIP attack in the patient's father, the diagnosis was established after genetic and biochemical examinations. At the age of 29, eight months after delivery of her first and only child, the patient was hospitalized due to a first proven attack of AIP. In the following years she suffered several premenstrual AIP attacks, with clinical symptoms ranging from abdominal pain to paralysis. One attack was accompanied by an increased urinary catecholamine output, strongly indicating adrenergic hyperactivity. The precipitation of acute episodes by secretion of gonadotrophins and a severe hyponatraemia due to a syndrome of inappropriate anti-diuretic hormone secretion indicated hypothalamic involvement in the pathogenesis of AIP. This patient has experienced an evolution of treatment regimens. At first, acute attacks were treated by i.v. hypertonic glucose. Afterwards propranolol was instituted as a maintenance therapy. Later on, i.v. injections of haem arginate were very successful in resolving acute AIP episodes. However, until therapy with an LHRH analogue was started, the patient continued to suffer premenstrual AIP attacks. These LHRH analogues cause hypothalamic inhibition of gonadotrophin secretion, with stabilization of endogenous ovarian steroid production at a low level, and therefore may be effective in preventing acute exacerbations of this disease. Since this patient went on a fixed regimen of an LHRH analogue combined with the lowest dose oestrogen patch her quality of life has improved substantially and she has not required hospitalization, now for over 3 years.  (+info)

Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. (7/197)

The aim of this retrospective study was to analyze the factors which affected the auxological response to GnRH agonist treatment and the final height (FH) outcome in 71 girls with idiopathic and truly precocious (onset before 8 years) central puberty (CTPP) who had been treated with the same therapy protocol (Decapeptyl Depot, 60 microg/kg i.m. every 28 days) for at least 2 years (since 7.0+/-1. 3 (S.D.) years of age) and followed until puberty was completed and FH was reached. During the entire treatment period we observed: (a) a decrease of height standard deviation scores (SDS) (from 1.5+/-1.7 to 0.9+/-1.3 SDS, P<0.01); (b) a striking deceleration of bone age (BA), revealed by the subnormal DeltaBA:Deltachronological age (CA) ratio (0.2+/-0.1); (c) an increase of predicted adult height (from 155.6+/-7.0 to 160.7+/-6.7 cm, P<0.0005). Treatment interruption was followed by an important catch-down growth, with an FH (158.4+/-5.8 cm) lower (P<0.025) than that predicted at the end of therapy. However, FH fell within the population norm and the target range in respectively 87.3 and 90% of the patients. The tallest FH was recorded in the patients who started therapy at less than 6 years of age and in those who discontinued treatment at a BA of 12.0--12.5 years. At stepwise regression analysis, FH in the whole study population was positively affected by the following independent factors: (a) height at the end of therapy (F=45.45, P<0.0001); (b) pretreatment height (F=13.91, P<0.0005); (c) treatment duration (F=8. 51, P<0.005); (d) target height (TH) (F=7.70, P<0.01). We conclude that: (i) most girls with idiopathic CTPP treated by GnRH agonists may achieve an adult height within the population norm and/or their target range; (ii) the height gain from therapy onset until FH attainment, however, is generally rather limited (on average 2.9 cm) and only few patients are able to reach their target percentile; (iii) the most favorable height prognosis with respect to TH is generally observed in the subjects with the tallest height at the end of treatment and the lowest BA2:CA2 ratio, due to the important deterioration of height prognosis which frequently follows therapy interruption; (iv) FH is also significantly conditioned by both TH and treatment duration; (v) in order to strengthen the weak therapeutic effect of GnRH agonists in CTPP this treatment should be started as early as possible and discontinued at a BA of 12.0--12.5 years.  (+info)

Luteal support with micronized progesterone following in-vitro fertilization using a down-regulation protocol with gonadotrophin-releasing hormone agonist: a comparative study between vaginal and oral administration. (8/197)

This study aimed to compare the efficacy of micronized progesterone administered as luteal support following ovulation induction for in-vitro fertilization (IVF)- embryo transfer in cycles using gonadotrophin-releasing hormone agonist, either orally (200 mgx4/day) or vaginally (100 mgx2/day) and to characterize the luteal phase hormonal profile during such treatments. A total of 64 high responder patients requiring intracytoplasmic sperm injection due to male factor infertility were prospectively randomized into two treatment groups. Patients treated orally or vaginally were comparable in age (31.9 +/- 6.1 versus 30.6 +/- 5.2; mean +/- SD), number of oocytes retrieved (17 +/- 8.2 versus 18 +/- 7.0), and number of embryos transferred (3.1 +/- 1.2 versus 2.7 +/- 0.9) per cycle. Following low dose vaginal treatment, a significantly higher implantation rate (30.7 versus 10.7%, P < 0.01), but similar clinical pregnancy rate (47.0 versus 33.3%) and ongoing pregnancy rate (41.1 versus 20.0%) was observed, compared with oral treatment. In conception cycles, luteal serum progesterone and oestrogen concentrations did not differ between the treatment groups. In non-conception cycles, late luteal progesterone concentrations were significantly lower following vaginal treatment. As low dose micronized progesterone administered vaginally is simple, easy and well tolerated, it could be recommended as the method of choice for luteal support, especially for high responder patients at risk for ovarian hyperstimulation syndrome.  (+info)

Triptorelin pamoate is a synthetic analogue of the natural hormone gonadotropin-releasing hormone (GnRH). It is used in the treatment of various conditions such as endometriosis, uterine fibroids, precocious puberty, and prostate cancer.

Triptorelin pamoate works by stimulating the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary gland, which in turn stimulate the production of sex hormones such as estrogen and testosterone. However, with continued use, it causes downregulation of the pituitary gland, leading to a decrease in the production of FSH and LH, and therefore a reduction in the levels of sex hormones.

The pamoate salt is used to slow down the release of triptorelin, allowing for longer-acting formulations that can be administered monthly or quarterly. The medication is usually given as an injection into a muscle (intramuscularly).

Pyrantel pamoate is an anthelmintic medication used to treat intestinal worm infections, such as pinworms, roundworms, and hookworms. It works by paralyzing the adult worms, which are then expelled from the body through the natural digestive process.

Pyrantel pamoate is available over-the-counter in various forms, including tablets, chewable tablets, and suspensions. The medication is typically taken as a single dose, but it may be repeated after two weeks for some types of worm infections.

It's important to note that while pyrantel pamoate can effectively treat intestinal worm infections, it does not prevent reinfection. Therefore, good hygiene practices, such as washing hands regularly and avoiding contact with contaminated soil or feces, are essential to reduce the risk of re-infection.

As with any medication, pyrantel pamoate should be taken under the guidance of a healthcare professional, especially in children, pregnant women, and people with certain medical conditions or who are taking other medications.

I'm sorry for any confusion, but "Pyrvinium compounds" is not a widely recognized medical term or category. Pyrvinium is an antiparasitic medication that is used to treat certain types of intestinal worm infections. The most common compound is Pyrvinium pamoate, which is the active ingredient in the branded medication "Vanquin."

Pyrvinium works by inhibiting the metabolism of the parasites, leading to their death and elimination from the body. It'… Read more

Luteolytic agents are substances that cause the breakdown or regression of the corpus luteum, a temporary endocrine structure in the ovary that forms after ovulation and produces progesterone during early pregnancy in mammals. These agents work by inhibiting the secretion of prostaglandins, which are necessary for maintaining the integrity of the corpus luteum. By causing the breakdown of the corpus luteum, luteolytic agents can induce menstruation or cause the termination of an early pregnancy. Examples of luteolytic agents include prostaglandin F2alpha (PGF2α) and its analogs, as well as certain dopamine agonists such as cabergoline. These agents are used in various clinical settings, including reproductive medicine and veterinary medicine.

Pyrantel is an anthelmintic medication used to treat and prevent gastrointestinal parasitic infections caused by roundworms, hookworms, and pinworms in humans and animals. It works by paralyzing the parasites, allowing them to be expelled from the body. Pyrantel is available in various formulations, including tablets, suspensions, and pastes, for human and veterinary use. Common brand names include Pin-X, Reese's Pinworm Medicine, and Strongid.

Ancylostomiasis is a parasitic infection caused by the hookworms, Ancylostoma duodenale and Necator americanus. These tiny worms infect the human intestines, specifically in the small intestine, where they attach themselves to the intestinal wall and feed on the host's blood.

The infection is typically acquired through skin contact with contaminated soil, particularly in areas where human feces are used as fertilizer or where there is poor sanitation. The larvae penetrate the skin, enter the bloodstream, and migrate to the lungs, where they mature further before being coughed up and swallowed, eventually reaching the small intestine.

Symptoms of ancylostomiasis can range from mild to severe and may include abdominal pain, diarrhea, anemia, weight loss, and fatigue. In severe cases, particularly in children or individuals with weakened immune systems, the infection can lead to protein-energy malnutrition, cognitive impairment, and even death.

Treatment for ancylostomiasis typically involves administration of anthelmintic medications such as albendazole or mebendazole, which kill the parasitic worms. Improved sanitation and hygiene practices can help prevent reinfection and reduce the spread of the disease.

Gonadotropin-Releasing Hormone (GnRH), also known as Luteinizing Hormone-Releasing Hormone (LHRH), is a hormonal peptide consisting of 10 amino acids. It is produced and released by the hypothalamus, an area in the brain that links the nervous system to the endocrine system via the pituitary gland.

GnRH plays a crucial role in regulating reproduction and sexual development through its control of two gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These gonadotropins, in turn, stimulate the gonads (ovaries or testes) to produce sex steroids and eggs or sperm.

GnRH acts on the anterior pituitary gland by binding to its specific receptors, leading to the release of FSH and LH. The hypothalamic-pituitary-gonadal axis is under negative feedback control, meaning that when sex steroid levels are high, they inhibit the release of GnRH, which subsequently decreases FSH and LH secretion.

GnRH agonists and antagonists have clinical applications in various medical conditions, such as infertility treatments, precocious puberty, endometriosis, uterine fibroids, prostate cancer, and hormone-responsive breast cancer.

Necatoriasis is a parasitic infection caused by the nematode (roundworm) Necator americanus, also known as the "New World hookworm." This condition is primarily found in areas with warm, moist climates and poor sanitation. The infection typically occurs when the larvae of the parasite penetrate the skin, usually through bare feet that come into contact with contaminated soil.

Once inside the human body, the larvae migrate to the lungs, where they mature and are coughed up and swallowed. They then reside in the small intestine, where they feed on blood and cause symptoms such as abdominal pain, diarrhea, anemia, and growth retardation in children. Necatoriasis is usually treated with anthelmintic medications like albendazole or mebendazole. Preventive measures include wearing shoes in areas where the parasite is common and improving sanitation to reduce the spread of contaminated soil.

Ancylostoma is a genus of parasitic roundworms that are commonly known as hookworms. These intestinal parasites infect humans and other animals through contact with contaminated soil, often via the skin or mouth. Two species of Ancylostoma that commonly infect humans are Ancylostoma duodenale and Ancylostoma ceylanicum.

Ancylostoma duodenale is found primarily in tropical and subtropical regions, including parts of the Mediterranean, Africa, Asia, and southern Europe. It can cause a disease called ancylostomiasis or hookworm infection, which can lead to symptoms such as abdominal pain, diarrhea, anemia, and impaired growth in children.

Ancylostoma ceylanicum is found mainly in Southeast Asia, southern China, and some parts of Australia. It can also cause ancylostomiasis, with symptoms similar to those caused by Ancylostoma duodenale. However, Ancylostoma ceylanicum infections are often less severe than those caused by Ancylostoma duodenale.

Preventive measures for hookworm infection include wearing shoes in areas where the soil may be contaminated with feces, washing hands thoroughly after using the toilet or handling soil, and avoiding ingestion of contaminated soil or water. Treatment for hookworm infection typically involves administration of anthelmintic drugs to eliminate the parasites from the body.

Equine strongyle infections refer to parasitic diseases caused by various species of Strongylus spp. and other related nematode (roundworm) parasites that infect horses. The term "strongyles" is used to describe large and small strongyles, which have different clinical significance and life cycles.

1. Large Strongyles (Strongylus vulgaris, S. edentatus, and S. equinus): These parasites have a significant clinical impact on horses. They have a complex life cycle involving migratory larval stages that travel through the horse's circulatory system and cause damage to blood vessels, heart, liver, and lungs. The adult strongyles reside in the large intestine and lay eggs, which are passed in the feces and further infect the horse upon ingestion of contaminated pasture.
2. Small Strongyles (Cyathostominae subfamily): These parasites have a simpler life cycle and are less clinically significant compared to large strongyles. The larvae encyst within the intestinal wall, where they can remain dormant for extended periods. When environmental conditions become favorable, these larvae emerge from their cysts and mature into adults in the large intestine, causing damage and potentially leading to clinical signs of disease.

Clinical signs of strongyle infections may include diarrhea, colic, weight loss, anemia, and decreased performance. Diagnosis is typically made by identifying parasite eggs in fecal samples using microscopic examination or coprological techniques. Treatment involves the use of anthelmintics (dewormers) specifically labeled for strongyle infections in horses. Preventative measures include pasture management, strategic deworming programs, and regular fecal egg count monitoring to assess parasite burden and treatment efficacy.

Antinematodal agents are a type of medication used to treat infections caused by nematodes, which are also known as roundworms. These agents work by either killing the parasitic worms or preventing them from reproducing. Some examples of antinematodal agents include albendazole, ivermectin, and mebendazole. These medications are used to treat a variety of nematode infections, such as ascariasis, hookworm infection, and strongyloidiasis. It is important to note that the use of antinematodal agents should be under the guidance of a healthcare professional, as they can have side effects and may interact with other medications.

Necator americanus is a species of parasitic hookworm that primarily infects the human intestine. The medical definition of Necator americanus would be:

A nematode (roundworm) of the family Ancylostomatidae, which is one of the most common causes of human hookworm infection worldwide. The adult worms live in the small intestine and feed on blood, causing iron deficiency anemia and protein loss. Infection occurs through contact with contaminated soil, often through bare feet, and results in a skin infection called cutaneous larva migrans (creeping eruption). After penetrating the skin, the larvae migrate to the lungs, ascend the respiratory tract, are swallowed, and then mature into adults in the small intestine.

The life cycle of Necator americanus involves several developmental stages, including eggs, larvae, and adult worms. The eggs are passed in the feces of infected individuals and hatch in warm, moist soil. The larvae then mature and become infective, able to penetrate human skin upon contact.

Preventive measures include wearing shoes in areas with known hookworm infection, avoiding walking barefoot on contaminated soil, improving sanitation and hygiene practices, and treating infected individuals to break the transmission cycle. Treatment of hookworm infection typically involves administration of anthelmintic medications, such as albendazole or mebendazole, which kill the adult worms in the intestine.

Acedapsone is not a recognized or established medical term. It does not have a specific medical definition in the context of pharmacology, clinical medicine, or medical research.

However, Acedapsone is an investigational antibiotic that has been studied in clinical trials for its potential to treat various bacterial infections. It is a nitrofuran derivative and functions as an inhibitor of bacterial DNA synthesis. Despite some promising results from early studies, further development of Acedapsone as a therapeutic agent seems to have stalled, and it is not currently approved for use in any country.

In summary, while Acedapsone has been explored as a potential antibiotic, it does not have an official medical definition and is not widely used in clinical practice.

"Trichuris" is a genus of parasitic roundworms that are known to infect the intestines of various mammals, including humans. The species that commonly infects humans is called "Trichuris trichiura," which is also known as the human whipworm. These worms are named for their long, thin shape that resembles a whip.

The life cycle of Trichuris involves ingestion of eggs containing infective larvae through contaminated food or water. Once inside the human body, the larvae hatch and migrate to the large intestine, where they mature into adult worms that live in the caecum and colon. Adult female worms lay thousands of eggs every day, which are passed in the feces and can survive in the environment for years, waiting to infect a new host.

Infections with Trichuris trichiura can cause symptoms such as diarrhea, abdominal pain, bloating, and weight loss. In severe cases, it can lead to anemia, malnutrition, and impaired growth in children. Treatment for trichuriasis typically involves medication that kills the adult worms, such as albendazole or mebendazole.

Cestode infections, also known as tapeworm infections, are caused by the ingestion of larval cestodes (tapeworms) present in undercooked meat or contaminated water. The most common types of cestode infections in humans include:

1. Taeniasis: This is an infection with the adult tapeworm of the genus Taenia, such as Taenia saginata (beef tapeworm) and Taenia solium (pork tapeworm). Humans become infected by consuming undercooked beef or pork that contains viable tapeworm larvae. The larvae then mature into adult tapeworms in the human intestine, where they can live for several years, producing eggs that are passed in the feces.
2. Hydatid disease: This is a zoonotic infection caused by the larval stage of the tapeworm Echinococcus granulosus, which is commonly found in dogs and other carnivores. Humans become infected by accidentally ingesting eggs present in dog feces or contaminated food or water. The eggs hatch in the human intestine and release larvae that migrate to various organs, such as the liver or lungs, where they form hydatid cysts. These cysts can grow slowly over several years and cause symptoms depending on their location and size.
3. Diphyllobothriasis: This is an infection with the fish tapeworm Diphyllobothrium latum, which is found in freshwater fish. Humans become infected by consuming raw or undercooked fish that contain viable tapeworm larvae. The larvae mature into adult tapeworms in the human intestine and can cause symptoms such as abdominal pain, diarrhea, and vitamin B12 deficiency.

Preventing cestode infections involves practicing good hygiene, cooking meat thoroughly, avoiding consumption of raw or undercooked fish, and washing fruits and vegetables carefully before eating. In some cases, treatment with antiparasitic drugs may be necessary to eliminate the tapeworms from the body.

Trichuriasis is a parasitic infection caused by the nematode (roundworm) Trichuris trichiura, also known as the whipworm. This infection primarily affects the large intestine (cecum and colon). The main symptoms of trichuriasis include diarrhea, abdominal pain, and weight loss. In heavy infections, there can be severe complications such as anemia, growth retardation, and rectal prolapse. Trichuriasis is typically transmitted through the ingestion of contaminated soil containing Trichuris trichiura eggs, often through poor hygiene practices or exposure to contaminated food and water.

Anthelmintics are a type of medication used to treat infections caused by parasitic worms, also known as helminths. These medications work by either stunting the growth of the worms, paralyzing them, or killing them outright, allowing the body to expel the worms through normal bodily functions. Anthelmintics are commonly used to treat infections caused by roundworms, tapeworms, flukeworms, and hookworms. Examples of anthelmintic drugs include albendazole, mebendazole, praziquantel, and ivermectin.

Gonadal hormones, also known as sex hormones, are steroid hormones that are primarily produced by the gonads (ovaries in females and testes in males). They play crucial roles in the development and regulation of sexual characteristics and reproductive functions. The three main types of gonadal hormones are:

1. Estrogens - predominantly produced by ovaries, they are essential for female sexual development and reproduction. The most common estrogen is estradiol, which supports the growth and maintenance of secondary sexual characteristics in women, such as breast development and wider hips. Estrogens also play a role in regulating the menstrual cycle and maintaining bone health.

2. Progesterone - primarily produced by ovaries during the menstrual cycle and pregnancy, progesterone prepares the uterus for implantation of a fertilized egg and supports the growth and development of the fetus during pregnancy. It also plays a role in regulating the menstrual cycle.

3. Androgens - produced by both ovaries and testes, but primarily by testes in males. The most common androgen is testosterone, which is essential for male sexual development and reproduction. Testosterone supports the growth and maintenance of secondary sexual characteristics in men, such as facial hair, a deeper voice, and increased muscle mass. It also plays a role in regulating sex drive (libido) and bone health in both males and females.

In summary, gonadal hormones are steroid hormones produced by the gonads that play essential roles in sexual development, reproduction, and maintaining secondary sexual characteristics.

Precocious puberty is a medical condition where the onset of sexual maturation occurs at an unusually early age, typically before the age of 8 in girls and before the age of 9 in boys. It is characterized by the development of secondary sexual characteristics such as breast development or growth of facial hair, as well as the start of menstruation in girls. This condition can be caused by various factors including central nervous system abnormalities, genetic disorders, or exposure to certain hormones. Early diagnosis and treatment are important to prevent potential negative effects on growth, bone health, and psychosocial development.

Follicle-Stimulating Hormone (FSH) is a glycoprotein hormone secreted and released by the anterior pituitary gland. In females, it promotes the growth and development of ovarian follicles in the ovary, which ultimately leads to the maturation and release of an egg (ovulation). In males, FSH stimulates the testes to produce sperm. It works in conjunction with luteinizing hormone (LH) to regulate reproductive processes. The secretion of FSH is controlled by the hypothalamic-pituitary-gonadal axis and its release is influenced by the levels of gonadotropin-releasing hormone (GnRH), estrogen, inhibin, and androgens.

Antimony is a toxic metallic element with the symbol Sb and atomic number 51. It exists in several allotropic forms and can be found naturally as the mineral stibnite. Antimony has been used for centuries in various applications, including medicinal ones, although its use in medicine has largely fallen out of favor due to its toxicity.

In a medical context, antimony may still be encountered in certain medications used to treat parasitic infections, such as pentavalent antimony compounds (e.g., sodium stibogluconate and meglumine antimoniate) for the treatment of leishmaniasis. However, these drugs can have significant side effects and their use is typically reserved for severe cases that cannot be treated with other medications.

It's important to note that exposure to antimony in high concentrations or over prolonged periods can lead to serious health issues, including respiratory problems, skin irritation, gastrointestinal symptoms, and even neurological damage. Therefore, handling antimony-containing substances should be done with caution and appropriate safety measures.

Hormone antagonists are substances or drugs that block the action of hormones by binding to their receptors without activating them, thereby preventing the hormones from exerting their effects. They can be classified into two types: receptor antagonists and enzyme inhibitors. Receptor antagonists bind directly to hormone receptors and prevent the hormone from binding, while enzyme inhibitors block the production or breakdown of hormones by inhibiting specific enzymes involved in their metabolism. Hormone antagonists are used in the treatment of various medical conditions, such as cancer, hormonal disorders, and cardiovascular diseases.

LHRH (Luteinizing Hormone-Releasing Hormone) receptors are a type of G protein-coupled receptor found on the surface of certain cells in the body, most notably in the anterior pituitary gland. These receptors bind to LHRH, a hormone that is produced and released by the hypothalamus in the brain.

When LHRH binds to its receptor, it triggers a series of intracellular signaling events that ultimately lead to the release of two other hormones from the anterior pituitary gland: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These hormones play critical roles in regulating reproductive function, including the development and maturation of sex cells (sperm and eggs), the production of sex steroid hormones (such as testosterone and estrogen), and the regulation of the menstrual cycle in females.

Disorders of the LHRH receptor or its signaling pathway can lead to a variety of reproductive disorders, including precocious puberty, delayed puberty, and infertility.

Ovulation induction is a medical procedure that involves the stimulation of ovulation (the release of an egg from the ovaries) in women who have difficulties conceiving due to ovulatory disorders. This is typically achieved through the use of medications such as clomiphene citrate or gonadotropins, which promote the development and maturation of follicles in the ovaries containing eggs. The process is closely monitored through regular ultrasounds and hormone tests to ensure appropriate response and minimize the risk of complications like multiple pregnancies. Ovulation induction may be used as a standalone treatment or in conjunction with other assisted reproductive technologies (ART), such as intrauterine insemination (IUI) or in vitro fertilization (IVF).

Antineoplastic agents, hormonal, are a class of drugs used to treat cancers that are sensitive to hormones. These agents work by interfering with the production or action of hormones in the body. They can be used to slow down or stop the growth of cancer cells and may also help to relieve symptoms caused by the spread of cancer.

Hormonal therapies can work in one of two ways: they can either block the production of hormones or prevent their action on cancer cells. For example, some hormonal therapies work by blocking the action of estrogen or testosterone, which are hormones that can stimulate the growth of certain types of cancer cells.

Examples of hormonal agents used to treat cancer include:

* Aromatase inhibitors (such as letrozole, anastrozole, and exemestane), which block the production of estrogen in postmenopausal women
* Selective estrogen receptor modulators (such as tamoxifen and raloxifene), which block the action of estrogen on cancer cells
* Luteinizing hormone-releasing hormone agonists (such as leuprolide, goserelin, and triptorelin), which block the production of testosterone in men
* Antiandrogens (such as bicalutamide, flutamide, and enzalutamide), which block the action of testosterone on cancer cells

Hormonal therapies are often used in combination with other treatments, such as surgery or radiation therapy. They may be used to shrink tumors before surgery, to kill any remaining cancer cells after surgery, or to help control the spread of cancer that cannot be removed by surgery. Hormonal therapies can also be used to relieve symptoms and improve quality of life in people with advanced cancer.

It's important to note that hormonal therapies are not effective for all types of cancer. They are most commonly used to treat breast, prostate, and endometrial cancers, which are known to be sensitive to hormones. Hormonal therapies may also be used to treat other types of cancer in certain situations.

Like all medications, hormonal therapies can have side effects. These can vary depending on the specific drug and the individual person. Common side effects of hormonal therapies include hot flashes, fatigue, mood changes, and sexual dysfunction. Some hormonal therapies can also cause more serious side effects, such as an increased risk of osteoporosis or blood clots. It's important to discuss the potential risks and benefits of hormonal therapy with a healthcare provider before starting treatment.

Luteinizing Hormone (LH) is a glycoprotein hormone, which is primarily produced and released by the anterior pituitary gland. In women, a surge of LH triggers ovulation, the release of an egg from the ovaries during the menstrual cycle. During pregnancy, LH stimulates the corpus luteum to produce progesterone. In men, LH stimulates the testes to produce testosterone. It plays a crucial role in sexual development, reproduction, and maintaining the reproductive system.

Parasitic sensitivity tests, also known as parasite drug susceptibility tests, refer to laboratory methods used to determine the effectiveness of specific antiparasitic medications against a particular parasitic infection. These tests help healthcare providers identify which drugs are most likely to be effective in treating an individual's infection and which ones should be avoided due to resistance or increased risk of side effects.

There are several types of parasitic sensitivity tests, including:

1. In vitro susceptibility testing: This involves culturing the parasite in a laboratory setting and exposing it to different concentrations of antiparasitic drugs. The growth or survival of the parasite is then observed and compared to a control group that was not exposed to the drug. This helps identify the minimum inhibitory concentration (MIC) of the drug, which is the lowest concentration required to prevent the growth of the parasite.
2. Molecular testing: This involves analyzing the genetic material of the parasite to detect specific mutations or gene variations that are associated with resistance to certain antiparasitic drugs. This type of testing can be performed using a variety of methods, including polymerase chain reaction (PCR) and DNA sequencing.
3. Phenotypic testing: This involves observing the effects of antiparasitic drugs on the growth or survival of the parasite in a laboratory setting. For example, a parasite may be grown in a culture medium and then exposed to different concentrations of a drug. The growth of the parasite is then monitored over time to determine the drug's effectiveness.

Parasitic sensitivity tests are important for guiding the treatment of many parasitic infections, including malaria, tuberculosis, and leishmaniasis. These tests can help healthcare providers choose the most effective antiparasitic drugs for their patients, reduce the risk of drug resistance, and improve treatment outcomes.

Ovarian Hyperstimulation Syndrome (OHSS) is a medical condition characterized by the enlargement of the ovaries and the accumulation of fluid in the abdominal cavity, which can occur as a complication of fertility treatments that involve the use of medications to stimulate ovulation.

In OHSS, the ovaries become swollen and may contain multiple follicles (small sacs containing eggs) that have developed in response to the hormonal stimulation. This can lead to the release of large amounts of vasoactive substances, such as vascular endothelial growth factor (VEGF), which can cause increased blood flow to the ovaries and fluid leakage from the blood vessels into the abdominal cavity.

Mild cases of OHSS may cause symptoms such as bloating, abdominal pain or discomfort, nausea, and diarrhea. More severe cases can lead to more serious complications, including blood clots, kidney failure, and respiratory distress. In extreme cases, hospitalization may be necessary to manage the symptoms of OHSS and prevent further complications.

OHSS is typically managed by monitoring the patient's symptoms and providing supportive care, such as fluid replacement and pain management. In severe cases, medication or surgery may be necessary to drain excess fluid from the abdominal cavity. Preventive measures, such as adjusting the dosage of fertility medications or canceling treatment cycles, may also be taken to reduce the risk of OHSS in high-risk patients.

I couldn't find a medical definition specifically for "delayed-action preparations." However, in the context of pharmacology, it may refer to medications or treatments that have a delayed onset of action. These are designed to release the active drug slowly over an extended period, which can help to maintain a consistent level of the medication in the body and reduce the frequency of dosing.

Examples of delayed-action preparations include:

1. Extended-release (ER) or controlled-release (CR) formulations: These are designed to release the drug slowly over several hours, reducing the need for frequent dosing. Examples include extended-release tablets and capsules.
2. Transdermal patches: These deliver medication through the skin and can provide a steady rate of drug delivery over several days. Examples include nicotine patches for smoking cessation or fentanyl patches for pain management.
3. Injectable depots: These are long-acting injectable formulations that slowly release the drug into the body over weeks to months. An example is the use of long-acting antipsychotic injections for the treatment of schizophrenia.
4. Implantable devices: These are small, biocompatible devices placed under the skin or within a body cavity that release a steady dose of medication over an extended period. Examples include hormonal implants for birth control or drug-eluting stents used in cardiovascular procedures.

Delayed-action preparations can improve patient compliance and quality of life by reducing dosing frequency, minimizing side effects, and maintaining consistent therapeutic levels.

Schistosomiasis, also known as bilharzia or snail fever, is a parasitic infection caused by several species of the trematode flatworm Schistosoma. The infection occurs when people come into contact with freshwater contaminated with the parasite's larvae, which are released by infected freshwater snails.

The larvae penetrate the skin, enter the bloodstream, and mature into adult worms in the blood vessels of the urinary tract or intestines. The female worms lay eggs, which can cause inflammation and scarring in various organs, including the liver, lungs, and brain.

Symptoms of schistosomiasis may include fever, chills, cough, muscle aches, and diarrhea. In chronic cases, the infection can lead to serious complications such as kidney damage, bladder cancer, and seizures. Schistosomiasis is prevalent in tropical and subtropical regions with poor sanitation and lack of access to safe drinking water. It is preventable through improved water supply, sanitation, and snail control measures. Treatment typically involves the use of a medication called praziquantel, which kills the adult worms.

Antiprotozoal agents are a type of medication used to treat protozoal infections, which are infections caused by microscopic single-celled organisms called protozoa. These agents work by either killing the protozoa or inhibiting their growth and reproduction. They can be administered through various routes, including oral, topical, and intravenous, depending on the type of infection and the severity of the illness.

Examples of antiprotozoal agents include:

* Metronidazole, tinidazole, and nitazoxanide for treating infections caused by Giardia lamblia and Entamoeba histolytica.
* Atovaquone, clindamycin, and pyrimethamine-sulfadoxine for treating malaria caused by Plasmodium falciparum or other Plasmodium species.
* Pentamidine and suramin for treating African trypanosomiasis (sleeping sickness) caused by Trypanosoma brucei gambiense or T. b. rhodesiense.
* Nitroimidazoles, such as benznidazole and nifurtimox, for treating Chagas disease caused by Trypanosoma cruzi.
* Sodium stibogluconate and paromomycin for treating leishmaniasis caused by Leishmania species.

Antiprotozoal agents can have side effects, ranging from mild to severe, depending on the drug and the individual patient's response. It is essential to follow the prescribing physician's instructions carefully when taking these medications and report any adverse reactions promptly.

Drug antagonism is a type of interaction between two or more drugs, where one drug (known as the antagonist) reduces or blocks the effects of another drug (known as the agonist). This can occur through various mechanisms, such as binding to the same receptor site as the agonist and preventing it from activating the receptor, or by increasing the metabolism or excretion of the agonist.

Drug antagonism is often used in medical treatment to counteract the negative effects of certain drugs. For example, naloxone is an opioid antagonist that can be used to reverse the respiratory depression caused by opioid overdose. Similarly, flumazenil is a benzodiazepine antagonist that can be used to reverse the sedative effects of benzodiazepines in cases of overdose or adverse reactions.

However, drug antagonism can also lead to unintended consequences, such as when one medication reduces the effectiveness of another medication that a patient is taking for a different condition. Therefore, it is important for healthcare providers to be aware of potential drug interactions and to carefully monitor their patients' responses to medications.

Estradiol is a type of estrogen, which is a female sex hormone. It is the most potent and dominant form of estrogen in humans. Estradiol plays a crucial role in the development and maintenance of secondary sexual characteristics in women, such as breast development and regulation of the menstrual cycle. It also helps maintain bone density, protect the lining of the uterus, and is involved in cognition and mood regulation.

Estradiol is produced primarily by the ovaries, but it can also be synthesized in smaller amounts by the adrenal glands and fat cells. In men, estradiol is produced from testosterone through a process called aromatization. Abnormal levels of estradiol can contribute to various health issues, such as hormonal imbalances, infertility, osteoporosis, and certain types of cancer.

The pituitary gland is a small, endocrine gland located at the base of the brain, in the sella turcica of the sphenoid bone. It is often called the "master gland" because it controls other glands and makes the hormones that trigger many body functions. The pituitary gland measures about 0.5 cm in height and 1 cm in width, and it weighs approximately 0.5 grams.

The pituitary gland is divided into two main parts: the anterior lobe (adenohypophysis) and the posterior lobe (neurohypophysis). The anterior lobe is further divided into three zones: the pars distalis, pars intermedia, and pars tuberalis. Each part of the pituitary gland has distinct functions and produces different hormones.

The anterior pituitary gland produces and releases several important hormones, including:

* Growth hormone (GH), which regulates growth and development in children and helps maintain muscle mass and bone strength in adults.
* Thyroid-stimulating hormone (TSH), which controls the production of thyroid hormones by the thyroid gland.
* Adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to produce cortisol and other steroid hormones.
* Follicle-stimulating hormone (FSH) and luteinizing hormone (LH), which regulate reproductive function in both males and females.
* Prolactin, which stimulates milk production in pregnant and lactating women.

The posterior pituitary gland stores and releases two hormones that are produced by the hypothalamus:

* Antidiuretic hormone (ADH), which helps regulate water balance in the body by controlling urine production.
* Oxytocin, which stimulates uterine contractions during childbirth and milk release during breastfeeding.

Overall, the pituitary gland plays a critical role in maintaining homeostasis and regulating various bodily functions, including growth, development, metabolism, and reproductive function.

Intracytoplasmic Sperm Injection (ICSI) is a specialized form of assisted reproductive technology (ART), specifically used in the context of in vitro fertilization (IVF). It involves the direct injection of a single sperm into the cytoplasm of a mature egg (oocyte) to facilitate fertilization. This technique is often used when there are issues with male infertility, such as low sperm count or poor sperm motility, to increase the chances of successful fertilization. The resulting embryos can then be transferred to the uterus in hopes of achieving a pregnancy.

Embryo transfer is a medical procedure that involves the transfer of an embryo, which is typically created through in vitro fertilization (IVF), into the uterus of a woman with the aim of establishing a pregnancy. The embryo may be created using the intended parent's own sperm and eggs or those from donors. After fertilization and early cell division, the resulting embryo is transferred into the uterus of the recipient mother through a thin catheter that is inserted through the cervix. This procedure is typically performed under ultrasound guidance to ensure proper placement of the embryo. Embryo transfer is a key step in assisted reproductive technology (ART) and is often used as a treatment for infertility.

An ovary is a part of the female reproductive system in which ova or eggs are produced through the process of oogenesis. They are a pair of solid, almond-shaped structures located one on each side of the uterus within the pelvic cavity. Each ovary measures about 3 to 5 centimeters in length and weighs around 14 grams.

The ovaries have two main functions: endocrine (hormonal) function and reproductive function. They produce and release eggs (ovulation) responsible for potential fertilization and development of an embryo/fetus during pregnancy. Additionally, they are essential in the production of female sex hormones, primarily estrogen and progesterone, which regulate menstrual cycles, sexual development, and reproduction.

During each menstrual cycle, a mature egg is released from one of the ovaries into the fallopian tube, where it may be fertilized by sperm. If not fertilized, the egg, along with the uterine lining, will be shed, leading to menstruation.

Endometrial neoplasms refer to abnormal growths or tumors in the endometrium, which is the innermost lining of the uterus. These neoplasms can be benign (non-cancerous) or malignant (cancerous). The two main types of endometrial cancer are type I, also known as endometrioid adenocarcinoma, and type II, which includes serous carcinoma, clear cell carcinoma, and carcinosarcoma.

Type I endometrial cancers are usually estrogen-dependent and associated with risk factors such as obesity, diabetes, and prolonged exposure to estrogen without progesterone. They tend to grow more slowly and have a better prognosis than type II cancers.

Type II endometrial cancers are less common but more aggressive, often presenting at an advanced stage and having a worse prognosis. They are not typically associated with hormonal factors and may occur in women who have gone through menopause.

Endometrial neoplasms can also include benign growths such as polyps, hyperplasia, and endometriosis. While these conditions are not cancerous, they can increase the risk of developing endometrial cancer and should be monitored closely by a healthcare provider.

Fertilization in vitro, also known as in-vitro fertilization (IVF), is a medical procedure where an egg (oocyte) and sperm are combined in a laboratory dish to facilitate fertilization. The fertilized egg (embryo) is then transferred to a uterus with the hope of establishing a successful pregnancy. This procedure is often used when other assisted reproductive technologies have been unsuccessful or are not applicable, such as in cases of blocked fallopian tubes, severe male factor infertility, and unexplained infertility. The process involves ovarian stimulation, egg retrieval, fertilization, embryo culture, and embryo transfer. In some cases, additional techniques such as intracytoplasmic sperm injection (ICSI) or preimplantation genetic testing (PGT) may be used to increase the chances of success.

"Decapeptyl SR 11.25mg (triptorelin pamoate) - Patient Information Leaflet (PIL) - (emc)". www.medicines.org.uk. Retrieved 2022- ... Triptorelin has been used as a chemical castration agent for reducing sexual urges in sex offenders. Triptorelin is a ... triptorelin is marketed under the brand name Variopeptyl. In the UK and Germany, it is sold as Salvacyl. Triptorelin and other ... Triptorelin, sold under the brand name Decapeptyl among others, is a medication that acts as an agonist analog of gonadotropin- ...

No FAQ available that match "triptorelin pamoate"

No images available that match "triptorelin pamoate"